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Abstract
Background: Patients with rheumatic diseases including rheumatoid arthritis (RA) are at increased risk for
infections related to both the disease and its treatments. These include uncommonly reported infections due to
histoplasmosis.
Methods: Medical record review of all patients with a diagnosis of RA who developed new histoplasmosis
infection in an endemic region between Jan 1, 1998 and Jan 30, 2009 and who were seen at Mayo Clinic in
Rochester, Minnesota was performed.
Results: Histoplasmosis was diagnosed in 26 patients. Most patients were on combination therapies; 15 were on
anti-tumor necrosis factor (anti-TNF) agents, 15 on corticosteroids and 16 on methotrexate. Most received more
than 6 months of itraconazole and/or amphotericin treatment. Two patients died of causes unrelated to
histoplasmosis. Anti-TNF treatment was restarted in 4/15 patients, with recurrence of histoplasmosis in one.
Conclusions: In this largest single center series of patients with RA and histoplasmosis in the era of
immunomodulatory therapy, we found that most patients had longstanding disease and were on multiple
immunomodulatory agents. Most cases were pulmonary; typical signs and symptoms of disease were frequently
lacking.
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Background
Histoplasma capsulatum is a dimorphic fungus widely
distributed in nature and is limited to the Midwest and
Southeastern United States. After inhalation, the fungus
transforms into a pathogenic yeast form. Optimal host
defense against Histoplasma capsulatum requires inter-
action between macrophages and T-cells. Patients with
rheumatic diseases receiving immunomodulatory and
immunosuppressive therapies may be at increased risk
for histoplasmosis, although reports of this infectious
complication in this population primarily derived from
case reports.
The most recent epidemiologic information for histo-
plasmosis was described in large urban outbreaks in
Indianapolis that occurred between 1978 and 1993. The
rate of dissemination of histoplasmosis from these studies
has been cited at 0.46 per 1000 infected persons [1].
However immunosuppression has been a clearly identi-
fied risk factor in disseminated disease, and extrapulmon-
ary disease occurs especially in immunocompromised
patients [2]. Known immunosuppressive conditions
noted to increase the risk of dissemination include
acquired immunodeficiency syndrome, organ transplant,
hematologic malignancies, and immunosuppressive
agents [3].
Histoplasmosis occurs in patients with rheumatoid
arthritis (RA) who receive corticosteroid therapy, disease
modifying antirheumatic therapies such as methotrexate,
and has been reported in post-marketing surveillance of
patients receiving anti-tumor necrosis factor (TNF) ther-
apy [4]. We describe the occurrence and risk factors for
histoplasmosis in adult patients with RA in an endemic
region in the era of anti-TNF therapies.
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We conducted a retrospective review of all patients with
a diagnosis of RA who developed histoplasmosis and
were seen at Mayo Clinic in Rochester, Minnesota
between January 1, 1998 and January 30th, 2009. The
Mayo Clinic Institutional Review Board approved the
study.
The Mayo Clinic electronic medical record database
was used to identify all adult patients (≥18 years of age)
who were coded with the diagnosis of RA during the
study period. All patients met the American College of
Rheumatology classification criteria for RA [5]. Detailed
information for each patient was abstracted from the
medical record and included demographics, medical
comorbidities including human immunodeficiency virus
(HIV) and malignancy, date of diagnosis of RA, disease
modifying antirheumatic drug (DMARD) therapies
including biologic response modifiers and corticosteroid
(CS) use, and the presence of coexisting infection at the
time of diagnosis of histoplasmosis. Patient vital status
and cause of death were recorded.
The Mayo Clinic Department of Laboratory Medicine
and Pathology’s clinical microbiology database was also
used to screen and verify the diagnosis of histoplasmo-
sis. Histoplasma infection was diagnosed by any of the
following criteria: histopathology consistent with Histo-
plasma capsulatum by Gomori methenamine silver
stain; positive culture of any tissue demonstrating Histo-
plasma capsulatum; a positive urine, serum or cere-
brospinal fluid for Histoplasma capsulatum antigen by
enzyme immunoassay screening; and Histoplasma anti-
body serology ≥1 : 8d o n eb yc o m p l e m e n tf i x a t i o no ra
positive immunodiffusion test with the presence of M or
H and M bands [6]. Supporting radiographic informa-
tion included chest imaging (chest radiography or chest
computed tomography scanning) at time of diagnosis.
All patients with RA and a verified diagnosis of active
histoplasmosis were identified and included in the study
analysis. Clinical signs and symptoms including fever,
hepatosplenomegaly, respiratory, gastrointestinal, mus-
culoskeletal, central nervous system findings, weight
loss, lymphadenopathy and skin findings attributable to
the histoplasmosis infection at time of infection were
abstracted when available. The antifungal treatment his-
tory including timing and type of antifungal agent was
retrieved. The DMARD regimen at time of Histoplasma
infection and during treatment was recorded.
Results
Twenty-six patients with a verified diagnosis of RA and
meeting inclusion criteria for histoplasmosis were identi-
fied between January 1, 1998 and January 30, 2009. The
characteristics of these patients are included in table 1.
Fifteen patients were male and eleven were female. The
mean age at the time of Histoplasma infection was 59.6
years (standard deviation, SD, 12.8), with mean duration
of follow up of 2.1 years (SD 2.3). The mean duration of
RA at the time of diagnosis of histoplasmosis was 10.5
years (SD 7.5). The most common comorbidity was
chronic lung disease, found in 5 patients; and none had
HIV or hepatitis B or C infection. Four patients had an
underlying malignancy. Fifteen (58%) patients were hos-
pitalized for diagnosis or management of their histoplas-
mosis, and 5 of these (19%) required initial treatment in
a critical care unit. There were two deaths (8%) at time
of last follow up. Neither death was as attributable to
histoplasmosis.
Twenty-five of the 26 patients (96%) were on DMARD
therapy with or without CS at the time of diagnosis of
histoplasmosis. The most common DMARDs were
methotrexate (81%) and anti-TNF agents (58%). Other
therapies included hydroxychloroquine (19%) and leflu-
nomide (19%). Fifty-eight percent of patients were on
concurrent CS therapy (prednisone, average daily dose
of 9.5 mg). Most (88%) were on combination therapy
Table 1 Summary of 26 patients with rheumatoid
arthritis who developed histoplasmosis infection
Characteristic Number (%) or
years
Male 15 (58%)
Age, years (mean; range) 60 (32 - 78)
Duration of rheumatoid arthritis, years (mean;
range)
10.5 (0.5 - 24)
Current disease modifying antirheumatic drug
therapy
25 (96%)
Hospitalized for infection 15 (58%)
Duration of follow up, years (mean; range) 2.1 (0 - 7.9)
Patient deaths 2 (5%)
Medication Number (%)
Methotrexate 21 (81%)
Prednisone (average dose: 9.1 mg) 15 (58%)
Hydroxychloroquine 5 (19%)
Leflunomide 5 (19%)
Anti-TNF Agent 15 (58%)
Adalimumab 7 (27%)
Infliximab 6 (23%)
Etanercept 2 (8%)
Basis for Histoplasmosis Diagnosis Number positive
(%)
Fever 19 (73%)
Abnormal chest imaging (X-ray or CT) 22 (85%)
Histoplasma serology 23 (88%)
Histoplasma culture 14 (54%)
Histoplasma urinary antigen 13 (50%)
Histoplasma biopsy histopathology 12 (46%)
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diagnosis: 3 patients (12%) were on 4, 9 patients (35%)
were on 3 and 11 patients (42%) were on 2 concomitant
DMARDs (table 2). Anti-TNF agents included etaner-
cept (2 patients; 8%), adalimumab (7 patients; 27%), and
infliximab (6 patients; 23%). The immunomodulatory
agents are summarized in table 1. The median time on
anti-TNF therapy prior to histoplasma infection was 15
months (range: 2-132). The duration of treatment for
each anti-TNF agent at the time of histoplasmosis is
listed in table 2.
The duration of symptoms prior to diagnosis of histo-
plasmosis was less than 4 weeks in 14 patients, 5 to 12
weeks in 10 patients and greater than 12 weeks in 2
patients. The lung was the site of infection in 14
patients. Nine patients had pulmonary disease and disse-
mination to an additional site including: liver or spleen
involvement in 3 patients, fungemia in 2 patients, bone
marrow involvement with fungemia in 2 patients, bone
marrow involvement in one and small bowel involve-
ment in one. The remaining 3 patients had disseminated
disease without documented pulmonary involvement;
one had fungemia, one had bone marrow involvement
with fungemia and one had liver involvement with fun-
gemia. Five patients had coexistent bacterial infections
(Staphylococcus aureus, viridans group Streptococcus,
Enterobacteriaceae, Bacteroides sp. and Nocardia
asteroides).
Fever (>38°C) was the most common clinical manifes-
tation of histoplasmosis at presentation (19 patients).
Chest imaging (conventional radiograph or computed
tomography) was obtained in 25 of 26 patients, includ-
ing conventional radiograph in 24 patients at the time
of diagnosis. The most common finding on plain chest
radiograph was a focal pneumonitis in 9 patients, fol-
lowed by an isolated pulmonary nodule in 5 patients.
Computed tomography (CT) of the chest was obtained
in 19 patients. The most common findings on CT were
pulmonary nodules in 15 patients, hilar/mediastinal lym-
phadenopathy in 14 patients, and alveolar infiltrates in 7
patients.
Histoplasma antibody tests were obtained in all
patients and were positive in 23 of the 26 patients. His-
toplasma urinary antigen was obtained in 24 patients,
and 13 were positive. Yeast cells of Histoplasma capsu-
latum were found in biopsies from 12 patients (8 lung
tissue, 2 from bone marrow biopsy, and one each from
liver and small bowel biopsy). Fungal cultures were
obtained in 25 patients and 14 were positive; 8 had posi-
tive cultures from a pulmonary source (sputum, bron-
chial washings, and biopsy), 7 patients had positive
blood cultures, 2 patients had positive bone marrow cul-
tures and 1 had a positive small bowel tissue/peritoneal
culture.
Antifungal therapy for histoplasmosis was adminis-
tered to 24 of the 26 patients (92%). All treatment regi-
mens included azoles. Itraconazole was used in 22,
voriconazole in 4 and fluconazole in 2 patients. Nine of
the 26 patients (35%) received an initial course of
amphotericin (liposomal amphotericin), usually for 2
weeks in conjunction with an azole. The duration of
antifungal therapy varied according to the clinical syn-
drome. Two patients with pulmonary histoplasmosis
were untreated; the infection could be confirmed by
biopsy in only one of them. The second untreated
patient had a positive serology (H band only) and hilar
lymphadenopathy on chest CT, and the diagnosis of
acute histoplasmosis infection was in question.
Of 9 patients with pulmonary histoplasmosis and
negative or unknown Histoplasma urinary antigen, 2
were treated for 12 months, and 5 were treated for less
than 12 months. Of 5 patients with pulmonary histo-
plasmosis and a positive Histoplasma urinary antigen,
one was treated for greater than 12 months, 2 were trea-
ted for 12 months and 2 patients were treated for 6
months. There were 12 patients with systemic histoplas-
mosis: one had lung and small bowel involvement and
was treated indefinitely, 3 patients (lung with spleen,
lung with liver, liver with fungemia) were treated for
greater than 12 months, 5 patients (involvement of lung
and bone marrow and fungemia in one; lung with fun-
gemia in two, lung with liver in one, and lung with bone
marrow in one) were treated for 12 months, and 3
patients (one with fungemia, one with lung, bone mar-
row and fungemia, and one with involvement of bone
marrow with fungemia) were treated for less than 12
months.
Two of the patients died at time of last follow up. One
patient had a pre-existent pulmonary adenocarcinoma.
T h es e c o n dp a t i e n td e v e l o p e dn o c a r d i o s i sa n dh e r p e s
simplex virus infection approximately 12 months follow-
ing completion of voriconazole therapy, and was treated
for these but died 3 months after discharge of unknown
causes.
Anti-TNF agents were discontinued in 14 of 15
patients taking these agents at time of diagnosis of the
infection. The one patient who did not discontinue anti-
TNF therapy had a lung biopsy to further assess pul-
monary infiltrates. The biopsy revealed histoplasma
granuloma but subsequent evaluation failed to reveal
evidence of active disease. The diffuse lung infiltrates
were felt to represent interstitial lung disease secondary
to RA and not acute histoplasmosis. The patient’sa n t i -
TNF treatment (infliximab) was continued without
interruption, and without development of overt
histoplasmosis.
At the time of last follow up after histoplasma infec-
tion, 10 of the remaining 14 patients had not restarted
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Patient
number
Age/
Sex
Anti-TNF
agent
Time to infection
from initiation of
anti-TNF agents
(months)
Other therapy Site of
infection
Diagnosis* Treatment
1 68/
M
Adalimumab 48 Methotrexate,
Prednisone
Lung Serology Itraconazole 3 months
2 60/
M
Adalimumab 3 Hydroxychloroquine,
Prednisone,
Leflunomide
Lung Serology Itraconazole > 12 months
3 64/
M
Adalimumab 2 None Lung Pathology (lung) Amphotericin 2 weeks,
voriconazole 3 months
4 62/
M
Adalimumab 12 Methotrexate,
Prednisone
Lung, liver Culture (lung), pathology
(lung), serology, urine
antigen
Amphotericin 2 weeks,
itraconazole > 12 months
5 47/F Adalimumab 4 Methotrexate,
Prednisone
Lung Pathology (sputum),
serology, urine antigen
Fluconazole 12 months
6 72/F Adalimumab 15 Methotrexate Lung,
bone
marrow,
fungemia
Culture (sputum, bone
marrow, blood), pathology
(lung), serology, urine
antigen
Amphotericin 2 weeks,
voriconazole 10 weeks,
itraconazole 12 months
7 47/F Adalimumab 33 Methotrexate Lung Culture (sputum), serology,
urine antigen
Itraconazole 16 weeks,
transition to fluconazole
12 weeks (6 months total)
8 37/F Etanercept 3 Methotrexate,
Hydroxychloroquine
Lung Serology No treatment
9 47/F Etanercept 2 Methotrexate Lung Serology Itraconazole 1 week
Voriconazole 12 months
10 59/
M
Infliximab 12 Methotrexate,
Prednisone,
Leflunomide
Liver,
fungemia
Culture (blood), pathology
(liver), serology, urine
antigen
Amphotericin 8 weeks,
voriconazole 6 months
transition to itraconazole
> 12 months
11 73/F Infliximab 24 Methotrexate,
Prednisone
Bone
marrow,
fungemia
Culture (blood, bone
marrow), serology
Itraconazole 3 months
(follow up elsewhere)
12 32/
M
Infliximab 18 Methotrexate,
Hydroxychloroquine,
Prednisone
Lung Culture (sputum), pathology
(lung), serology, urine
antigen
Amphotericin 2 weeks,
itraconazole > 12 months
13 68/F Infliximab 36 Prednisone Lung,
small
bowel
Culture (sputum, small
bowel, peritoneum),
pathology (small bowel)
serology, urine antigen
Amphotericin 4 weeks,
Itraconazole indefinitely
14 64/
M
Infliximab 132 Azathioprine,
Prednisone
Lung Pathology (lung), serology No treatment
15 53/F Infliximab 56 Methotrexate Lung Serology, urine antigen Voriconazole 1 week,
Itraconazole 12 months
16 52/
M
None N/A Methotrexate,
Prednisone
Lung,
bone
marrow,
fungemia
Culture (blood), pathology
(bone marrow), serology,
urine antigen
Amphotericin 1 week,
Itraconazole 6 months
17 68/
M
None N/A Methotrexate,
Prednisone,
Leflunomide
Lung Serology Itraconazole 5 months
18 68/
M
None N/A Methotrexate,
Prednisone
Lung,
bone
marrow
Culture (sputum), pathology
(lung, bone marrow),
serology, urine antigen
Itraconazole 12 months
19 70/
M
None N/A Methotrexate,
Prednisone,
Leflunomide
Fungemia Culture (blood) Itraconazole 6 months
20 63/
M
None N/A Methotrexate,
Prednisone
Lung,
Spleen
Culture (lung, sputum),
serology, urine antigen
Itraconazole > 12 months
21 62/F None N/A Methotrexate Lung,
fungemia
Culture (blood), serology Amphotericin 2 weeks,
itraconazole 12 months
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agents at the time of diagnosis and subsequently
restarted them later (patients 1,3,8,12; table 2). Of these,
three did not have a recurrence and one had a recur-
rence of clinical histoplasmosis (patient 12). This latter
patient had been on infliximab for 18 months at the
time of diagnosis of pulmonary histoplasmosis and was
treated with itraconazole for 6 months with an appropri-
ate clinical response. This was followed by re-introduc-
tion of adalimumab with continuation of itraconazole.
The patient was hospitalized with recurrent fevers and
an elevated histoplasma urinary antigen after 3 doses of
adalimumab. A diagnosis of recurrent pulmonary histo-
plasmosis was made and the patient was treated with
liposomal amphotericin for 2 weeks followed by itraco-
nazole for a total of 2 years of therapy. The patient
recovered from the histoplasmosis, and the anti-TNF
therapy was not subsequently restarted.
The second of the three patients (patient 1 in table 2)
whose anti-TNF therapy was resumed was diagnosed
with pulmonary histoplasmosis with a positive serology
and a pulmonary mass on CT with negative cultures and
urinary antigen. The patient had been treated with adali-
mumab for 4 years prior to the diagnosis of histoplasmo-
sis. Adalimumab was discontinued and the patient was
treated with three months of itraconazole with improve-
ment. Approximately one year after diagnosis of infec-
tion, the adalimumab was restarted. There was no
recurrence of infection noted at time of last follow up.
The final of the three patients in whom anti-TNF
therapy was resumed (patient 8) developed a febrile pul-
monary illness three months after initiation of etaner-
cept, which was then discontinued. The patient had
hilar lymphadenopathy on chest CT and a low positive
histoplasmosis serology (M band). The illness was self
limited and improved on antibiotics without antifungal
treatment. The etanercept was restarted 5 months after
the resolution of the respiratory illness. There was no
recurrence of pulmonary histoplasmosis in this patient
at time of last follow up.
Discussion
Histoplasmosis is endemic in the upper Midwest and
Southeastern United States, and can occur in immuno-
suppressed patients as an opportunistic infection. It is
infrequently reported in patients with RA. Immunomo-
dulatory therapies, including anti-TNF agents and CS,
pose a risk for development of histoplasmosis. The pre-
vention and management of this disease in endemic areas
poses significant challenges since most of the recommen-
dations regarding diagnosis and management are based
upon expert opinion [7]. Limited data suggests that serial
monitoring with serial histoplasma serologies or urinary
histoplasma antigen testing in a highly endemic area is
not helpful to identify these patients before the onset of
symptomatic disease [7]. Clinical decisions regarding dis-
continuing anti-TNF agents, use of preventive azole ther-
apy and the timing of restarting immunosuppressive
agents must be made in the face of considerable uncer-
tainly. Most of the available clinical information on histo-
plasmosis in patients receiving anti-TNF agents is based
upon case reports and small case series, with the largest
report a literature review of fungal infections complicat-
ing anti-TNF therapy [8]. In that study, 84 cases of histo-
plasmosis were identified. In cases where data were
available on the indication for anti-TNF therapy (42% of
total cases), the majority of patients (77%) had RA.
The criteria for the diagnosis of histoplasmosis in our
patient population is similar to other reported series.
Histoplasma serologic tests were positive in 88% of our
patients. This compares to previously reported sensitiv-
ities of this test in the 80% range [3,9]. Histoplasma
urinary antigen was found to be positive in 54% of
patients tested. In the subset of patients with dissemi-
nated disease 83% had a positive urinary antigen. The
Histoplasma urinary antigen test is also useful for fol-
lowing the response to therapy, and assess for recrudes-
cent infection [3]. CT and plain chest imaging was also
helpful in the diagnosis of active infection; 88% of
patients in this study had corroborative chest radiograph
or CT findings. Culture and histopathology results
Table 2 Clinical characteristics and treatment of 26 patients with rheumatoid arthritis who developed histoplasmosis
(Continued)
22 78/
M
None N/A Methotrexate,
Prednisone
Lung Culture (sputum), serology,
urine antigen
Itraconazole 6 months
23 68/
M
None N/A Methotrexate,
Leflunomide,
Minocycline
Lung,
fungemia
Culture (blood), serology,
urine antigen
Amphotericin 2 weeks,
Itraconazole 12 months
24 35/F None N/A None Lung Pathology (lung), serology Itraconazole 3 months
25 75/
M
None N/A Methotrexate,
Hydroxychloroquine
Lung Pathology (lung) Itraconazole 6 weeks
26 45/F None N/A Methotrexate,
Hydroxychloroquine
Lung, liver serology Itraconazole 12 months
F = female; M = male; N/A = not applicable.
*See Methods for description of tests
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seminated disease, and were positive in 54% and 46% of
our patients respectively.
Histoplasmosis in patients treated with immunomodu-
latory drugs including anti-TNF therapies may be the
result of reactivation of latent infection, or new expo-
sure (or reexposure) of hosts to the organism [10]. The
risk of development of serious invasive fungal infections
in patients on anti-TNF therapy has been increasingly
recognized over the past several years [8,11,12]. Ten
c a s e so fh i s t o p l a s m o s i si np a t i e n t st a k i n ga n t i - T N F
agents from post licensure surveillance from the
Adverse Event Reporting System (AERS) of the Food
and Drug Administration (FDA) have been published
[13]. In 2004, data from the AERS described an
increased rate of granulomatous infections among
patients on anti-TNF treatment [4]. In this series (1998
until 2002) there were 42 reported cases of histoplasmo-
sis after the first anti-TNF treatments were approved for
the treatment of rheumatoid arthritis in 1998. This asso-
ciation resulted in an FDA warning, issued on Septem-
ber 4, 2008, that notified healthcare professionals the
recognition of histoplasmosis in patients taking anti-
TNF agents may be associated with delays in treatment
that can ultimately result in death [14]. At the time of
this published warning, the FDA had reviewed 240 cases
of histoplasmosis in patients who had received inflixi-
mab (207 cases), etanercept (17 cases), adalimumab (16
cases) and certolizumab (1 case). There were 12 deaths
(5% of reviewed cases) noted in this report.
In the United States, the occurrence of tuberculosis in
patients on anti-TNF therapy (most commonly in the
first 90 days of treatment) supports reactivation of infec-
tion as the most likely mechanism of disease [4]. Reacti-
vation and new infection are both possible in patients
with RA treated with anti-TNF therapy [15]. The risk of
reactivation histoplasmosis in 586 patients who under-
went solid organ or bone marrow transplant in Indiana
was reported to be very low [16]. Indiana is a hyperen-
demic area of histoplasmosis with 50-80% of residents
having evidence of past infection as determined by skin
testing. Despite the fact that 18% of patients had posi-
tive pretransplant histoplasmosis serologic tests and 4%
had chest radiographs consistent with prior granuloma-
tous disease, none developed histoplasmosis during a 3
year follow up time period. Serologic or radiographic
evidence of prior histoplasmosis infection is not predic-
tive of disease in the studies immunocompromised
population.
In our population, the average time from initiation of
anti-TNF therapy to clinical infection was > 15 months,
making reactivation a less likely mode of acquisition of
disease. There is no published evidence about whether
granulomas on chest radiography in patients living in
histoplasmosis endemic areas are predictive of develop-
ment of histoplasmosis in patients on TNF-inhibitors.
One patient in our study had biopsy proven pulmonary
histoplasmosis. At that point the patient had been trea-
ted with anti-TNF therapy for 5 years without clinical
evidence of disease. Another patient in our study had
anti-TNF therapy restarted one year after treatment for
symptomatic documented pulmonary histoplasmosis and
had no evidence of reactivation of infection at time of
last follow up one year after resumption of anti-TNF
therapy.
T h ec u r r e n ts t u d yp r o v i d e ss o m ea s s i s t a n c et oc l i n i -
cians regarding restarting immunomodulatory therapy in
this group of patients. For the majority of patients on
anti-TNF agents in our study, the therapy was discon-
tinued at diagnosis and withheld throughout the period
of histoplasmosis treatment. Patients in this study with
disseminated disease were treated with azole therapy for
6 months or greater.
The most recent Infectious Disease Society of America
clinical practice guidelines on the management of
patients with histoplasmosis recommend 12 months of
azole treatment for disseminated disease [17]. The prior
guidelines however recommended 6-18 months of azole
treatment for disseminated disease in non-AIDS patients
[18]. The shorter treatment regimens in this patient
population likely reflect treatment according to the ear-
lier guideline. The treatment regimens in patients with
acute pulmonary histoplasmosis were more variable,
generally consisting of 3 months of azole treatment in
less severe infection to 12 months or longer in more
severe cases. The degree of immunodeficiency in RA
patients also must be considered. Patients who require
more intense immunosuppressive therapies for control
of RA may even benefit from longer therapy or even
lifelong suppressive therapy in select cases.
There are several limitations to this study. Although
this is the largest single center experience with histo-
plasmosis in patients with RA in the era of biologic
response modifiers, the number of patients is relatively
small and conclusions regarding risk factors for infec-
tion or outcome must be drawn with caution. Con-
founding variables, the endemic nature of
histoplasmosis, concomitant therapies and lack of epide-
miologic information make attribution of specific ther-
apy to histoplasmosis infection risk difficult. This was a
single center review with a patient population primarily
from Minnesota and neighboring states, the results of
which may not be generalizable to other geographic
areas. It is not a population based study, and we are
unable to accurately identify a total number of patients
exposed to each DMARD, including anti-TNF agents, to
use as a denominator in the assessment of relative risk
of developing histoplasmosis infection. Also, given the
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in the geographic area of this study, it is difficult to
clearly identify mechanisms of exposure that resulted in
disease.
How to screen for histoplasmosis and manage the
patient with RA who has potential histoplasma expo-
sure, lives in an endemic area for histoplasmosis, or has
had previous overt histoplasmosis and requires immuno-
modulatory therapy, including anti-TNF treatment may
be answered by further studies. At this point, we recom-
mend that all patients in endemic areas be screened for
a clinical history of histoplasmosis. Though chest radio-
graphy may not predict reactivation of histoplasmosis in
patients on TNF-inhibitors, we believe it is valuable to
determine pre-existing abnormalities in all patients in
whom immunomodulatory therapy, including CS, con-
ventional DMARD and biologic response modifier thera-
pies. These studies are helpful to evaluate for the
possibility of previous granulomatous infection, such as
coccidiodomycosis and tuberculosis which may alter
management strategies.
Screening with histoplasma urine antigen testing in
the asymptomatic patient is appears to be of no benefit
in predicting infection [7]. We have not found this to be
a valuable screening tool and also do not recommend it.
If there is evidence of previous exposure to histoplasma
in the absence of previous overt infection, we do not
recommend histoplasmosis prophylaxis. An important
limitation of this recommendation is that the actual risk
of reactivation of histoplasmosis is unknown, so that the
risk/benefit of prophylactic treatment is also unclear.
Clinicians should proceed with caution when consid-
ering resumption of anti-TNF therapy in patients who
clearly developed histoplasmosis infection while on anti-
TNF agents. There is evidence that itraconazole mainte-
nance therapy prevents relapse of histoplasmosis in
AIDS patients who are chronically immunocompro-
mised [19]. The risk of reactivation of severe histoplas-
mosis is unknown for any patient who was previously
treated for the infection and who is then re-challenged
with anti-TNF agents despite chronic azole therapy.
Azole maintenance therapy may be effective in such
patients who have reinstituted anti-TNF therapy [10].
Conclusions
To our knowledge, this is the largest single center
review of histoplasmosis in patients with RA in the era
of anti-TNF agents. The patients who developed histo-
plasmosis had longstanding RA (greater than 10 years)
and were treated with multiple immunomodulatory
agents, with 88% of patients on more than one agent at
time of diagnosis. More than 50% of RA patients who
developed histoplasmosis during the 11 year study per-
iod were on anti-TNF treatment. Infection can occur at
any time after initiation of anti-TNF therapy, so that a
high index of suspicion is required for febrile patients
with pulmonary symptoms. Histoplasma serologic tests
were frequently positive in this patient population and
remain useful diagnostic tools. Forty six percent of
patients in our study had severe disseminated, extrapul-
monary disease.
Prolonged treatment regimens with azole therapy are
often required to resolve the disease. It is prudent to
discontinue anti-TNF agents at time of infection.
Resumption of immunomodulatory therapies including
anti-TNF therapy must be undertaken cautiously in
patients who developed histoplasmosis while on anti-
TNF therapy as there is a risk of serious relapse of the
infection despite suppressive antifungal therapy. The
majority of cases may be secondary to reinfection rather
than reactivation. There are no accepted screening stra-
tegies to assess patients at risk for infection, so that clin-
icians and patients must maintain vigilance for the
possibility of development of active histoplasmosis.
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